Letrozol Labormed

Letrozole, the active ingredient in Letrozol Labormed, is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of postmenopausal estrogen receptor‑positive breast cancer, helping to lower estrogen levels that can drive tumor growth.

GNH USA supplies Letrozol Labormed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole belongs to the aromatase inhibitor class and is used in hormone‑dependent breast cancer management. - Postmenopausal estrogen receptor‑positive breast cancer: reduces recurrence risk and slows disease progression. - Adjuvant therapy for hormone‑receptor positive breast cancer: improves disease‑free survival after surgery. - Metastatic breast cancer in postmenopausal women: helps control tumor growth and extends survival.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver dysfunction: jaundice, elevated enzymes. - Bone fracture: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: sudden shortness of breath, chest pain. - Myocardial infarction: heart attack symptoms. - Anaphylaxis: severe allergic reaction with swelling and airway compromise. - Elevated cholesterol: significant rise in blood lipid levels.

Before initiating Letrozole therapy, several safety considerations should be addressed. - Bone health monitoring: assess bone mineral density regularly. - Liver function testing: check hepatic enzymes before and during treatment. - Cardiovascular risk assessment: evaluate history of heart disease or clotting disorders. - Concomitant hormone therapy review: avoid estrogen‑containing products. - Use in premenopausal women: contraindicated unless ovarian suppression is confirmed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen replacement therapy: negates aromatase inhibition. - Tamoxifen: antagonistic effects on estrogen pathways. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower Letrozole plasma levels. - Warfarin: may increase anticoagulant effect, requiring close INR monitoring.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): may raise Letrozole concentrations. - Statins: potential additive effect on liver enzymes. - Glucocorticoids: may enhance bone loss risk. - Antidepressants (SSRIs): possible increase in hot‑flash severity. - Antifungal azoles: may modestly increase Letrozole exposure.